Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth

The cellular responses to two new temozolomide (TMZ) analogues, DP68 and DP86, acting against glioblastoma multiforme (GBM) cell lines and primary culture models are reported. Dose-response analysis of cultured GBM cells revealed that DP68 is more potent than DP86 and TMZ and that DP68 was effective even in cell lines resistant to TMZ. Based on a serial neurosphere assay, DP68 inhibits repopulation of these cultures at low concentrations. The efficacy of these compounds was independent of MGMT and MMR functions. DP68-induced interstrand DNA crosslinks were demonstrated with H2O2-treated cells. Furthermore, DP68 induced a distinct cell cycle arrest with accumulation of cells in S phase that is not observed for TMZ. Consistent with this biological response, DP68 induces a strong DNA damage response, including phosphorylation of ATM, Chk1 and Chk2 kinases, KAP1, and histone variant H2AX. Suppression of FANCD2 expression or ATR expression/kinase activity enhanced anti-glioblastoma effects of DP68. Initial pharmacokinetic analysis revealed rapid elimination of these drugs from serum. Collectively, these data demonstrate that DP68 is a novel and potent anti-glioblastoma compound that circumvents TMZ resistance, likely as a result of its independence from MGMT and mismatch repair and its capacity to crosslink strands of DNA.

[1]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[2]  R. Wheelhouse,et al.  Glioblastoma Multiforme Therapy and Mechanisms of Resistance , 2013, Pharmaceuticals.

[3]  R. Wheelhouse,et al.  Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53. , 2013, Journal of medicinal chemistry.

[4]  Junjie Chen,et al.  DNA damage tolerance: a double-edged sword guarding the genome. , 2013, Translational cancer research.

[5]  I. Weissman,et al.  Brain Tumor Stem Cell Multipotency Correlates with Nanog Expression and Extent of Passaging in Human Glioblastoma Xenografts , 2013, Oncotarget.

[6]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[7]  I. Pollack,et al.  Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome , 2012, Molecular Cancer Research.

[8]  S. Choi,et al.  The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. , 2012, Translational oncology.

[9]  J. Sarkaria,et al.  Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts , 2012, Clinical Cancer Research.

[10]  C. Laughton,et al.  Certain Imidazotetrazines Escape O6-Methylguanine-DNA Methyltransferase and Mismatch Repair , 2011, Oncology.

[11]  Erika Pastrana,et al.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells. , 2011, Cell stem cell.

[12]  A. Ross,et al.  Cancer esearch apeutics , Targets , and Chemical Biology ecretase Inhibitors Enhance Temozolomide Treatment uman Gliomas by Inhibiting Neurosphere R opulation and Xenograft Recurrence , 2010 .

[13]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[14]  J. Sarkaria,et al.  Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model , 2009, Journal of Neuro-Oncology.

[15]  Gunnar Brunborg,et al.  The comet assay: topical issues. , 2008, Mutagenesis.

[16]  J. Leppänen,et al.  Large neutral amino acid transporter enables brain drug delivery via prodrugs. , 2008, Journal of medicinal chemistry.

[17]  A. D’Andrea,et al.  The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents , 2007, Journal of Molecular Medicine.

[18]  A. Ivanov,et al.  KAP1, a novel substrate for PIKK family members, colocalizes with numerous damage response factors at DNA lesions. , 2006, Cancer research.

[19]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[20]  M. Bibby,et al.  Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs. , 2006, European journal of medicinal chemistry.

[21]  C. James,et al.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.

[22]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[23]  Michael S Kallos,et al.  New tissue dissociation protocol for scaled-up production of neural stem cells in suspension bioreactors. , 2004, Tissue engineering.

[24]  S. Osman,et al.  Metabolic activation of temozolomide measured in vivo using positron emission tomography. , 2003, Cancer research.

[25]  A. Pegg.  Repair of O6-alkylguanine by alkyltransferases , 2000 .

[26]  M. Stevens,et al.  NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. , 1994, Biochemistry.

[27]  S P Langdon,et al.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.

[28]  T. Smyth,et al.  Hydrolysis of diazomethane-kinetics and mechanism , 1980 .

[29]  R. Wheelhouse,et al.  A Strategy for Imidazotetrazine Prodrugs with Anti-cancer Activity Independent of MGMT and MMR , 2015 .

[30]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[31]  M. Stevens,et al.  Temozolomide: mechanisms of action, repair and resistance. , 2012, Current molecular pharmacology.

[32]  T. Ward,et al.  Influence of extracellular pH on the cytotoxicity and DNA damage of a series of indolequinone compounds. , 2001, Anticancer research.

[33]  A. Pegg.  Repair of O(6)-alkylguanine by alkyltransferases. , 2000, Mutation research.

[34]  M. Stevens,et al.  Antitumour imidazotetrazines. Part 39. Synthesis of bis(imidazotetrazine)s with saturated spacer groups , 2000 .

[35]  M. Stevens,et al.  Decomposition of the antitumour drug temozolomide in deuteriated phosphate buffer: methyl group transfer is accompanied by deuterium exchange , 1993 .

[36]  Y. Shealy,et al.  Imidazoles. II. 5(or 4)-(Monosubstituted triazeno)imidazole-4(or 5)-carboxamides. , 1966, Journal of medicinal chemistry.

[37]  Shealy Yf,et al.  Imidazoles. II. 5(or 4)-(Monosubstituted triazeno)imidazole-4(or 5)-carboxamides. , 1966 .